ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1249

Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells

Carolina Duarte1, Lora Boteva2, Timothy Vyse1 and Michelle Fernando1, 1Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, 2MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoimmunity and interferons, B cells, Gene Expression, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic autoimmune disease characterized by autoantibody production and up-regulation of type 1 interferons (IFNs). The strongest genetic association in Europeans is tagged by the HLA-DRB1*03:01 extended haplotype, located in the MHC region on chromosome 6. Due to tight linkage disequilibrium and high polymorphism, the molecular mechanisms underlying the DRB1*03:01 association remain elusive. Coding and non-coding variants arising from this haplotype may play a role in disease susceptibility through regulating gene expression in a context-specific manner.

We therefore sought to investigate the effect of the SLE susceptibility factors (i) IFN-α and (ii) the DRB1*03:01 haplotype on gene expression in ex vivo B cells.

Methods: Fifty healthy European women harbouring DRB1*03:01 homozygous (n=17), heterozygous (n=3) and non-DRB1*03:01 (n=30) haplotypes were included in the study. RNA was extracted from negatively-selected ex vivoB cells at rest (n=49) and after stimulation with IFN-α (n=33). Genome-wide gene expression levels were quantified using the Affymetrix Human Exon 1.0 ST array and TaqMan qPCR. Differential expression was calculated using an ANOVA in Partek Genomics Suite and R (FDR<1%).

Results: Thirty-three per cent (5,163 / 15,468) of genes genome-wide are differentially expressed between resting and IFN-α-treated cells. Forty per cent of SLE (p=4×10-2) and 53% (p=6×10-6) of RA susceptibility genes from genome-wide association studies are significantly enriched in this data set, compared to IBD (30%, p=0.07).

As expected, these include members of the type 1 IFN pathway, such as the SLE risk genes IRF7 (fold change, FC=7.2) and STAT4 (FC=6.8). Interestingly, a number of SLE genes outside canonical type 1 IFN pathways are significantly down-regulated in response to IFN-α, including FCGR2B (FC=-2.7), ETS1 (FC=-1.7) and NCF2 (FC=-2.3). In addition, IFN-α decreases the expression of genes implicated in familial SLE, such as the B cell survival gene, PRKCD (FC=-1.2).

Furthermore, we find that the MHC class II gene, HLA-DPB1, is significantly up-regulated in DRB1*03:01 haplotypes compared to non-DRB1*03:01haplotypes at a similar level in resting cells and IFN-α-stimulated cells (FC=1.2).

Conclusion: Stimulation of B cells with IFN-α significantly alters expression of genes associated with idiopathic and familial SLE not previously reported to be involved in the type 1 IFN response. Down-regulation of a number of these genes by IFN-α parallels previously reported loss-of-function polymorphisms associated with SLE susceptibility. We also report a cis-eQTL (expression quantitative trait locus) between the DRB1*03:01 haplotype and HLA-DPB1, implicating a role for this haplotype in gene regulation. These data shed light into the role of IFN-α in the aetiopathogenesis of SLE and implicate HLA-DPB1 as an additional candidate gene underlying the DRB1*03:01 association with autoimmunity.


Disclosure: C. Duarte, None; L. Boteva, None; T. Vyse, None; M. Fernando, None.

To cite this abstract in AMA style:

Duarte C, Boteva L, Vyse T, Fernando M. Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/differential-expression-of-sle-susceptibility-genes-by-interferon-alpha-and-the-hla-drb10301-haplotype-in-ex-vivo-b-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-expression-of-sle-susceptibility-genes-by-interferon-alpha-and-the-hla-drb10301-haplotype-in-ex-vivo-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology